Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
41
PCRX Quote, Financials, Valuation and Earnings
Last price:
$21.91
Seasonality move
:
4.18%
Day range:
$22.03 - $23.73
52-week range:
$18.80 - $27.64
Dividend yield:
0%
P/E ratio:
50.64x
P/S ratio:
1.46x
P/B ratio:
1.34x
Volume:
2.1M
Avg. volume:
882.2K
1-year change:
-11.34%
Market cap:
$971.9M
Revenue:
$701M
EPS (TTM):
$0.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PCRX
Pacira Biosciences, Inc.
|
$201.9M | $0.90 | 10.43% | 608.41% | $29.71 |
|
ADMA
ADMA Biologics, Inc.
|
$139.8M | $0.20 | 23.95% | 81.82% | $25.67 |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$113M | $0.09 | 58.25% | -98.33% | $34.50 |
|
CRMD
CorMedix, Inc.
|
$127M | $0.81 | 178.58% | 96.01% | $14.86 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.18 | 31.89% | 267.32% | $14.50 |
|
KRYS
Krystal Biotech, Inc.
|
$105.1M | $1.61 | 27.28% | 16.24% | $313.22 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PCRX
Pacira Biosciences, Inc.
|
$22.59 | $29.71 | $971.9M | 50.64x | $0.00 | 0% | 1.46x |
|
ADMA
ADMA Biologics, Inc.
|
$15.18 | $25.67 | $3.6B | 17.83x | $0.00 | 0% | 7.64x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$28.57 | $34.50 | $3.5B | -- | $0.00 | 0% | 9.91x |
|
CRMD
CorMedix, Inc.
|
$7.35 | $14.86 | $579.1M | 3.58x | $0.00 | 0% | 2.47x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.33 | $14.50 | $4.5B | -- | $0.00 | 0% | 7.01x |
|
KRYS
Krystal Biotech, Inc.
|
$276.36 | $313.22 | $8.1B | 40.38x | $0.00 | 0% | 21.25x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PCRX
Pacira Biosciences, Inc.
|
36.9% | -0.996 | 38.41% | 3.38x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -3.277 | 2.38% | 3.53x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
37.61% | -0.523 | 3.21% | 2.83x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.679 | 0.48% | 1.60x |
|
FOLD
Amicus Therapeutics, Inc.
|
61.73% | -0.293 | 10.04% | 1.72x |
|
KRYS
Krystal Biotech, Inc.
|
0.76% | -0.723 | 0.13% | 9.28x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PCRX
Pacira Biosciences, Inc.
|
$130.9M | $13.2M | 1.58% | 2.81% | 7.33% | $57M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$117.8M | $18.4M | -6% | -10.26% | 14.2% | $26.2M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
FOLD
Amicus Therapeutics, Inc.
|
$156.8M | $15.9M | -4.09% | -12.36% | 8.61% | $16M |
|
KRYS
Krystal Biotech, Inc.
|
$99M | $44.3M | 19.06% | 19.22% | 41.33% | $75.4M |
Pacira Biosciences, Inc. vs. Competitors
-
Which has Higher Returns PCRX or ADMA?
ADMA Biologics, Inc. has a net margin of 3.03% compared to Pacira Biosciences, Inc.'s net margin of 27.14%. Pacira Biosciences, Inc.'s return on equity of 2.81% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital PCRXPacira Biosciences, Inc.72.93% $0.12 $1.2B ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About PCRX or ADMA?
Pacira Biosciences, Inc. has a consensus price target of $29.71, signalling upside risk potential of 31.54%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 69.08%. Given that ADMA Biologics, Inc. has higher upside potential than Pacira Biosciences, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Pacira Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PCRXPacira Biosciences, Inc.3 2 0 ADMAADMA Biologics, Inc.3 0 0 -
Is PCRX or ADMA More Risky?
Pacira Biosciences, Inc. has a beta of 0.244, which suggesting that the stock is 75.601% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.502%.
-
Which is a Better Dividend Stock PCRX or ADMA?
Pacira Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira Biosciences, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCRX or ADMA?
Pacira Biosciences, Inc. quarterly revenues are $179.5M, which are larger than ADMA Biologics, Inc. quarterly revenues of $134.2M. Pacira Biosciences, Inc.'s net income of $5.4M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Pacira Biosciences, Inc.'s price-to-earnings ratio is 50.64x while ADMA Biologics, Inc.'s PE ratio is 17.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira Biosciences, Inc. is 1.46x versus 7.64x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCRXPacira Biosciences, Inc.1.46x 50.64x $179.5M $5.4M ADMAADMA Biologics, Inc.7.64x 17.83x $134.2M $36.4M
-
Which has Higher Returns PCRX or ARQT?
Arcutis Biotherapeutics, Inc. has a net margin of 3.03% compared to Pacira Biosciences, Inc.'s net margin of 13.43%. Pacira Biosciences, Inc.'s return on equity of 2.81% beat Arcutis Biotherapeutics, Inc.'s return on equity of -10.26%.
Company Gross Margin Earnings Per Share Invested Capital PCRXPacira Biosciences, Inc.72.93% $0.12 $1.2B ARQTArcutis Biotherapeutics, Inc.90.98% $0.13 $303.7M -
What do Analysts Say About PCRX or ARQT?
Pacira Biosciences, Inc. has a consensus price target of $29.71, signalling upside risk potential of 31.54%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $34.50 which suggests that it could grow by 20.76%. Given that Pacira Biosciences, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe Pacira Biosciences, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PCRXPacira Biosciences, Inc.3 2 0 ARQTArcutis Biotherapeutics, Inc.5 1 0 -
Is PCRX or ARQT More Risky?
Pacira Biosciences, Inc. has a beta of 0.244, which suggesting that the stock is 75.601% less volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.702, suggesting its more volatile than the S&P 500 by 70.199%.
-
Which is a Better Dividend Stock PCRX or ARQT?
Pacira Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira Biosciences, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCRX or ARQT?
Pacira Biosciences, Inc. quarterly revenues are $179.5M, which are larger than Arcutis Biotherapeutics, Inc. quarterly revenues of $129.5M. Pacira Biosciences, Inc.'s net income of $5.4M is lower than Arcutis Biotherapeutics, Inc.'s net income of $17.4M. Notably, Pacira Biosciences, Inc.'s price-to-earnings ratio is 50.64x while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira Biosciences, Inc. is 1.46x versus 9.91x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCRXPacira Biosciences, Inc.1.46x 50.64x $179.5M $5.4M ARQTArcutis Biotherapeutics, Inc.9.91x -- $129.5M $17.4M
-
Which has Higher Returns PCRX or CRMD?
CorMedix, Inc. has a net margin of 3.03% compared to Pacira Biosciences, Inc.'s net margin of 49.9%. Pacira Biosciences, Inc.'s return on equity of 2.81% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital PCRXPacira Biosciences, Inc.72.93% $0.12 $1.2B CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About PCRX or CRMD?
Pacira Biosciences, Inc. has a consensus price target of $29.71, signalling upside risk potential of 31.54%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 102.14%. Given that CorMedix, Inc. has higher upside potential than Pacira Biosciences, Inc., analysts believe CorMedix, Inc. is more attractive than Pacira Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PCRXPacira Biosciences, Inc.3 2 0 CRMDCorMedix, Inc.4 0 0 -
Is PCRX or CRMD More Risky?
Pacira Biosciences, Inc. has a beta of 0.244, which suggesting that the stock is 75.601% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.
-
Which is a Better Dividend Stock PCRX or CRMD?
Pacira Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira Biosciences, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCRX or CRMD?
Pacira Biosciences, Inc. quarterly revenues are $179.5M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Pacira Biosciences, Inc.'s net income of $5.4M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Pacira Biosciences, Inc.'s price-to-earnings ratio is 50.64x while CorMedix, Inc.'s PE ratio is 3.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira Biosciences, Inc. is 1.46x versus 2.47x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCRXPacira Biosciences, Inc.1.46x 50.64x $179.5M $5.4M CRMDCorMedix, Inc.2.47x 3.58x $104.3M $108.6M
-
Which has Higher Returns PCRX or FOLD?
Amicus Therapeutics, Inc. has a net margin of 3.03% compared to Pacira Biosciences, Inc.'s net margin of 0.91%. Pacira Biosciences, Inc.'s return on equity of 2.81% beat Amicus Therapeutics, Inc.'s return on equity of -12.36%.
Company Gross Margin Earnings Per Share Invested Capital PCRXPacira Biosciences, Inc.72.93% $0.12 $1.2B FOLDAmicus Therapeutics, Inc.84.64% $0.01 $716.6M -
What do Analysts Say About PCRX or FOLD?
Pacira Biosciences, Inc. has a consensus price target of $29.71, signalling upside risk potential of 31.54%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.19%. Given that Pacira Biosciences, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Pacira Biosciences, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PCRXPacira Biosciences, Inc.3 2 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is PCRX or FOLD More Risky?
Pacira Biosciences, Inc. has a beta of 0.244, which suggesting that the stock is 75.601% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.
-
Which is a Better Dividend Stock PCRX or FOLD?
Pacira Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira Biosciences, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCRX or FOLD?
Pacira Biosciences, Inc. quarterly revenues are $179.5M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $185.2M. Pacira Biosciences, Inc.'s net income of $5.4M is higher than Amicus Therapeutics, Inc.'s net income of $1.7M. Notably, Pacira Biosciences, Inc.'s price-to-earnings ratio is 50.64x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira Biosciences, Inc. is 1.46x versus 7.01x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCRXPacira Biosciences, Inc.1.46x 50.64x $179.5M $5.4M FOLDAmicus Therapeutics, Inc.7.01x -- $185.2M $1.7M
-
Which has Higher Returns PCRX or KRYS?
Krystal Biotech, Inc. has a net margin of 3.03% compared to Pacira Biosciences, Inc.'s net margin of 47.99%. Pacira Biosciences, Inc.'s return on equity of 2.81% beat Krystal Biotech, Inc.'s return on equity of 19.22%.
Company Gross Margin Earnings Per Share Invested Capital PCRXPacira Biosciences, Inc.72.93% $0.12 $1.2B KRYSKrystal Biotech, Inc.92.39% $1.70 $1.2B -
What do Analysts Say About PCRX or KRYS?
Pacira Biosciences, Inc. has a consensus price target of $29.71, signalling upside risk potential of 31.54%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $313.22 which suggests that it could grow by 13.34%. Given that Pacira Biosciences, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Pacira Biosciences, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PCRXPacira Biosciences, Inc.3 2 0 KRYSKrystal Biotech, Inc.10 0 0 -
Is PCRX or KRYS More Risky?
Pacira Biosciences, Inc. has a beta of 0.244, which suggesting that the stock is 75.601% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.493, suggesting its less volatile than the S&P 500 by 50.719%.
-
Which is a Better Dividend Stock PCRX or KRYS?
Pacira Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira Biosciences, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCRX or KRYS?
Pacira Biosciences, Inc. quarterly revenues are $179.5M, which are larger than Krystal Biotech, Inc. quarterly revenues of $107.1M. Pacira Biosciences, Inc.'s net income of $5.4M is lower than Krystal Biotech, Inc.'s net income of $51.4M. Notably, Pacira Biosciences, Inc.'s price-to-earnings ratio is 50.64x while Krystal Biotech, Inc.'s PE ratio is 40.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira Biosciences, Inc. is 1.46x versus 21.25x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCRXPacira Biosciences, Inc.1.46x 50.64x $179.5M $5.4M KRYSKrystal Biotech, Inc.21.25x 40.38x $107.1M $51.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 5.87% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 4.76% over the past day.
